Gosk-Bierska I, Adamiec R, Alexewicz P, Wysokinski W E
Department and Clinic of Angiology, University Medical School of Wroclaw, Wroclaw, Poland.
Int Angiol. 2002 Jun;21(2):128-33.
In order to compare hemostasis in diabetic and non-diabetic claudicants we evaluated endothelial (von Willebrand factor, vWF), rheologic (fibrinogen, hematocrit), coagulation system (thrombin-antithrombin complex, TAT) and platelet (platelet factor 4, PF4, aggregation on thrombin, collagen and ADP stimulation) parameters in both groups and healthy controls.
Twenty-five diabetic, 34 non-diabetic patients with claudication and 26 healthy individuals were enrolled into the study.
The severity of lower limbs ischemia was similar in two groups of claudicants but coronary heart disease and cerebral ischemia were significantly more common in diabetic than in non-diabetic claudicants. vWF level was significantly higher in diabetic than non-diabetic claudicants and healthy controls (184+/-43%, 147+/-43%, and 103+/-42%, respectively). Fibrinogen was significantly higher in diabetic and non-diabetic claudicants compared to controls (4.2+/-1.7, and 3.9+/-1.1, versus 2.9+/-0.5 g/l) and TAT plasma concentration was much higher in diabetic compare to non-diabetic patients and controls (9.8+/-4.4, 1.7+/-1.1, and 1.3+/-0.6 microg, respectively). PF4 concentration was significantly higher in non-diabetic patients with PAOD (34+/-29 UI/ml) when compare to healthy controls (14+/-9 UI/ml), but diabetic PAOD patients with the disease showed lower PF4 concentration (26+/-30 UI/ml). Platelet aggregation with all used activators was similar in all groups likewise hematocrit values, and platelet count.
Complicated DM is linked with significant endothelial perturbation when compared with healthy, but also with PAOD individuals; rheologic parameters are not different from those found in PAOD patients; coagulation system activation but not platelet hyperactivity is associated with DM complicated by PAOD when compared to both control groups.
为比较糖尿病和非糖尿病间歇性跛行患者的止血情况,我们评估了两组患者及健康对照者的内皮(血管性血友病因子,vWF)、血液流变学(纤维蛋白原、血细胞比容)、凝血系统(凝血酶 - 抗凝血酶复合物,TAT)和血小板(血小板因子4,PF4,对凝血酶、胶原和ADP刺激的聚集反应)参数。
25例糖尿病、34例非糖尿病间歇性跛行患者和26例健康个体纳入本研究。
两组间歇性跛行患者下肢缺血严重程度相似,但糖尿病患者冠心病和脑缺血的发生率显著高于非糖尿病间歇性跛行患者。糖尿病间歇性跛行患者的vWF水平显著高于非糖尿病间歇性跛行患者和健康对照者(分别为184±43%、147±43%和103±42%)。与对照组相比,糖尿病和非糖尿病间歇性跛行患者的纤维蛋白原显著升高(分别为4.2±1.7、3.9±1.1,而对照组为2.9±0.5 g/l);糖尿病患者的TAT血浆浓度显著高于非糖尿病患者和对照组(分别为9.8±4.4、1.7±1.1和1.3±0.6 μg)。与健康对照者(14±9 UI/ml)相比,非糖尿病外周动脉疾病(PAOD)患者的PF4浓度显著升高(34±29 UI/ml),但糖尿病PAOD患者的PF4浓度较低(26±30 UI/ml)。所有组中,使用所有激活剂时的血小板聚集情况以及血细胞比容值和血小板计数相似。
与健康个体以及PAOD患者相比,合并糖尿病时存在显著的内皮功能紊乱;血液流变学参数与PAOD患者无差异;与两个对照组相比,合并PAOD的糖尿病患者凝血系统激活,但血小板无活性亢进。